NHS Dorset holding statement for Alzheimer’s medication
Lecanemab and donanemab have received media attention following reporting of research results indicating they may slow the development of Alzheimer’s Disease. These drugs will not be made available in Dorset until they become licensed and the National Institute for Health and Care Excellence (NICE) have issued guidance on how they should be used (publication is not anticipated until at least 2024). Since this may represent a step change in the diagnosis and management of early Alzheimer’s Disease there will need to be significant developments to local services. Discussions to support these changes are in their infancy but have commenced.
Any questions or enquiries please use emails below
Health professionals firstname.lastname@example.org
Customer care Customer.CareTeam@nhsdorset.nhs.uk